Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 5Genitourinary 4Gastrointestinal 4Thoracic 3Sarcoma 3Lymphoid 3Gynecologic 3Plasma cell 2Other hematologic neoplasm 2NET 2Endocrine 2Head & Neck 1Breast 1

Conditions

Neuroendocrine Tumors 169Carcinoid Tumor 27Carcinoma, Neuroendocrine 22Neoplasms 16Gastro-enteropancreatic neuroendocrine tumor 16Adenoma, Islet Cell 15Pancreatic Neoplasms 12Neoplasm Metastasis 10Pheochromocytoma 8Paraganglioma 8Sarcoma 7Colorectal Neoplasms 7Carcinoma 7Neuroectodermal Tumors, Primitive 6Neuroblastoma 6Gastrointestinal Neoplasms 6Vipoma 5Somatostatinoma 5Gastrinoma 5Cholangiocarcinoma 5Carcinoma, Islet Cell 5Breast Neoplasms 5Small Cell Lung Carcinoma 4Serotonin Syndrome 4Digestive System Neoplasms 4Anus Neoplasms 4Thyroid Neoplasms 3Salivary Gland Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3

Interventions

lutetium Lu 177 dotatate 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Disease Progression × NET × Clear all
NCT04954820 2026-02-05

ReLUTH

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Recruiting
146 enrolled
EndocrineNET

Neuroendocrine Tumors, Disease Progression

NCT06472388 2024-06-25

EVENET

AC Camargo Cancer Center

Phase 2 Recruiting
100 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡